Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease

Progress in Neurobiology

Volumn 65, Issue 2, 2001, Pages 135-172

  Blum, David ^a,b   Torch, Sakina ^a   Lambeng, Nathalie ^c   Nissou, Marie France ^d   Benabid, Alim Louis ^a   Sadoul, Rémy ^a   Verna, Jean Marc ^a  

^a HÔPITAL MICHALLON   (France)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c CEA GRENOBLE   (France)

^d Laboratoire d'Immunologie   (France)

Author keywords

6 OHDA; Animal models; Apoptosis; Dopamine; MPP+; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE; DOPAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDOPAMINE; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; BRAIN MITOCHONDRION; CELL SPECIFICITY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; THEORY;

ANIMALS; APOPTOSIS; DOPAMINE; HUMANS; MPTP POISONING; NERVE DEGENERATION; OXIDOPAMINE; SYMPATHOLYTICS;

EID: 0034993599     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(01)00003-X     Document Type: Review

References (510)

1. Frequency of dementia in Parkinson disease
2. 2 in chromaffin cells
3. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
4. + induced oxygen radical formation with mitochondrial enzymes
5. The Bcl-2 protein family: Arbiters of cell survival
6. Regulation of JNK signaling by GSTp
7. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress
8. The biochemistry of Parkinson's disease
9. +): Regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation
10. Brain peroxidase and catalase in Parkinson disease
11. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls
12. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease
13. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
14. The Bcl-2 protein family
15. Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice
16. Death receptors: Signaling and modulation
17. Apoptosis control by death and decoy receptors
18. Glial pathology but absence of apoptotic nigral neurons in long- standing Parkinson's disease
19. ++ accumulation
20. Control of apoptosis by Rel/NF-kappaB transcription factors
21. Apoptosis and its role in human disease
22. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine- induced degeneration of nigrostriatal dopamine neurons
23. Dopamine neurotoxicity: Inhibition of mitochondrial respiration
24. Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice
25. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
26. Inhibitors of caspases and JNK, but not p38, increase dopaminergic neuronal survival following 1-methyl-4-pyridinium treatment
27. Lesions of central norepinephrine terminals with 6-OH-dopamine: Biochemistry and fine structure
28. p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells
29. 6-hydroxydopamine-induced Nuclear Factor KappaB activation in PC12 cells
30. Extracellular toxicity of 6-hydroxydopamine on PC12 cells
31. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease
32. Interaction between 6-hydroxydopamine and transferrin: 'Let my iron go'
33. Apoptosis without caspases: An inefficient molecular guillotine?
34. Apoptosis: Checkpoint at the mitochondrial frontier
35. Caspases induce cytochrome c release from mitochondria by activating cytosolic factors
36. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis
37. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons
38. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine
39. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid
40. 2 on iron-dependent DNA strand breaks and related processes in the neuroblastoma cell line SK-N-SH
41. Biochemical pathways of caspase activation during apoptosis
42. Programmed cell death: Does it play a role in Parkinson's disease?
43. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography
44. Bcl-2 overexpression attenuates dopamine-induced apoptosis in an immortalized neural cell line by suppressing the production of reactive oxygen species
45. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence
46. Criteria for diagnosing Parkinson's disease
47. Is idiopathic parkinsonism the consequence of an event or a process?
48. +) on mitochondrial membrane potential in cerebellar neurons: Interaction with the NMDA receptor
49. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases
50. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism
51. Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson's disease
52. Apaf1 and the apoptotic machinery
53. +-induced apoptosis depends on mitochondrial membrane potential and ATP synthase
54. A cautionary note on the use of the TUNEL stain to determine apoptosis
55. + selectively affects calcium homeostasis in mesencephalic cell cultures from embryonal C57/Bl6 mice
56. Conversion of Bcl-2 to a Bax-like death effector by caspases
57. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
58. +, a metabolite of MPTP, by brain synaptosomes
59. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: Suppression by clorgyline and deprenyl
60. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism
61. Delayed movement disorders after carbon monoxide poisoning
62. +-induced dopaminergic neuronal cell death: Role of caspases, ROS and JNK
63. Characterization of MPP(+)-induced cell death in a dopaminergic neuronal cell line: Role of macromolecule synthesis, cytosolic calcium, caspase, and Bcl-2-related proteins
64. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control
65. A one-hit model of cell death in inherited neuronal degenerations
66. Developmental cell death: Morphological diversity and multiple mechanisms
67. The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria
68. Modulation of cell death by Bcl-XL through caspase interaction
69. The iap genes: Unique arbitrators of cell death
70. Control of programmed cell death by the baculovirus genes p35 and iap
71. Global cerebral ischemia activates nuclear factor-κB prior to evidence of DNA fragmentation
72. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents
73. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
74. Caspases: The executioners of apoptosis
75. Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP): Endogenous factors underlying idiopathic parkinsonism?
76. The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9
77. 1-dopa-induced neurotoxic and apoptotic changes on cultured chromaffin cells
78. In vitro induction of apoptosis or differentiation by dopamine in an immortalized olfactory neuronal cell line
79. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons
80. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus
81. Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration
82. + binds to neuromelanin
83. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity
84. Wild-type but not Parkinson's disease-related Ala-53→Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli
85. The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53
86. Glutathione peroxidase, glial cells and Parkinson's disease
87. Long-term effect of MPTP in the mouse brain in relation to aging: Neurochemical and immunocytochemical analysis
88. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis
89. Oxidation and nitration of catecholamines by nitrogen oxides derived from nitric oxide
90. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues
91. Effect of 6-hydroxydopamine on polymerization of tubulin. Protection by superoxide dismutase, catalase, or anaerobic conditions
92. P53- and CD95-associated apoptosis in neurodegenerative diseases
93. Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine
94. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo
95. Caenorhabditis elegans EGL-1 disrupts the interaction of CED-9 with CED-4 and promotes CED-3 activation
96. Determination of the (R)- and (S)-enantiomers of salsolinol and N- methylsalsolinol by use of a chiral high-performance liquid chromatographic column
97. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
98. Independent human MAP kinase signal-transduction pathway defined by MEK and MKK isoforms
99. Mitochondria as the central control point of apoptosis
100. +) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- treated rat
101. Role of oxidative stress in the manganese and 1-methyl-4-(2′-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced apoptosis in PC12 cells
102. Endogenous inhibitors of caspases
103. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
104. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
105. Decreased ferritin levels in brain in Parkinson's disease
106. A cytoplasmic inhibitor of the JNK signal transduction pathway
107. +) cause rapid ATP depletion in isolated hepatocytes
108. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons
109. Bcl-x short is elevated following severe global ischaemia in rat brains
110. Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinum-induced toxicity of cultured fetal rat mesencephalic dopamine neurons
111. Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death
112. Signal transduction pathways that regulate cell survival and cell death
113. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes
114. Involvement of a caspase-3-like cysteine protease in 1-methyl-4-phenylpyridinium-mediated apoptosis of cultured cerebellar granule neurons
115. Human IAP-like protein regulates programmed cell death downstream of Bcl-xL and cytochrome c
116. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease
117. Verteilung von noradrenalin und dopamin im gehirn des menschen und ihn verholten bei erkrankungen des extrapyramidalen systems
118. Role of the Jun kinase pathway in the regulation of c-Jun expression and apoptosis in sympathetic neurons
119. Genetic control of programmed cell death in the nematode C. elegans
120. Mechanisms and functions of cell death
121. Altered gene expression in neurons during programmed cell death: Identification of c-jun as necessary for neuronal apoptosis
122. The history of parkinsonism
123. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
124. +-induced apoptosis in human SH- SY5Y neuroblastoma cells
125. 125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys
126. A Drosophila model of Parkinson's disease
127. Ageing and Parkinson's disease: Substantia nigra regional selectivity
128. Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment
129. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection
130. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys
131. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey
132. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations
133. Nucleosomal DNA fragmentation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice
134. Characterization of platelet-derived growth factor (PDGF) action on a mouse neuroblastoma cell line, NB41, by introduction of an antisense PDGF beta-receptor RNA
135. Selective role of glutathione in protecting human neural cells from dopamine-induced apoptosis
136. Manganese catalyzed auto-oxidation of dopamine to 6-hydroxydopamine in vitro
137. A susceptibility locus for Parkinson's disease maps to chromosome 2p13
138. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
139. Clastogenic and mutagenic actions of active species generated in the 6- hydroxydopamine/oxygen reaction: Effects of scavengers of active oxygen, iron, and metal chelating agents
140. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
141. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost?
142. Nature of inhibition of mitochondrial respiratory complex I by 6- hydroxydopamine
143. Mechanism of inhibition of mitochondrial respiratory complex I by 6- hydroxydopamine and its prevention by desferrioxamine
144. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine
145. Young-onset Parkinson's disease: A clinical review
146. Lewy bodies of Parkinson's disease contain neurofilament antigens
147. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study
148. Effect of 6-hydroxydopamine on murine hematopoietic stem cells: Enhanced cytotoxicity on megakaryocyte colony forming units
149. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration
150. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro
151. The central executioners of apoptosis: Caspases or mitochondria?
152. Apoptotic pathways: The roads to ruin
153. Mitochondria and apoptosis
154. The brain-stem lesions in Parkinsonism
155. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation
156. Possible role of NF-kappaB and p53 in the glutamate-induced pro-apoptotic neuronal pathway
157. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis
158. Transcription factor ATF2 regulation by the JNK signal transduction pathway
159. Selective interaction of JNK protein kinase isoforms with transcription factors
160. MRI, brain iron and experimental Parkinson's disease
161. A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death
162. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons
163. Modeling dopamine system dysfunction in experimental animals
164. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A
165. Neurotrophic factors prevent ceramide-induced apoptosis downstream of c-Jun N-terminal kinase activation in PC12 cells
166. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: Relevance to Parkinson's disease
167. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease
168. Increase in bax expression in substantia nigra following MPTP treatment of mice
169. 3H]dopamine: Impact of ascorbic acid and glutathione
170. Instrastriatal injection of dopamine results in DNA damage and apoptosis in rats
171. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease
172. Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: A nuclear microscopy study
173. 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra
174. Circling behavior in rats with partial, unilateral nigro-striatal lesions: Effect of amphetamine, apomorphine, and DOPA
175. Further studies on the generation of hydrogen peroxide by 6- hydroxydopamine. Potentiation by ascorbic acid
176. Inhibition of biogenic amine uptake by hydrogen peroxide: Mechanism for toxic effects of 6-hydroxydopamine
177. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity
178. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse
179. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB
180. Programmed cell death in Caenorhabditis elegans
181. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2
182. Lasting N-terminal phosphorylation of c-Jun and activation of JNK/SAPK kinases neuronal injury
183. Mitogen-activated protein kinase phosphatases inactivate stress-activated protein kinase pathways in vivo
184. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
185. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An X-ray microanalysis
186. Neuronal vulnerability in Parkinson's disease
187. Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice
188. Genetic control of programmed cell death in the nematode Caenorhabditis elegans
189. Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: Interactions with and differences from glutamate-induced cell death
190. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation
191. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4
192. A clinicopathologic study of 100 cases of Parkinson's disease
193. A role for the tumour suppressor gene p53 in regulating neuronal apoptosis
194. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease
195. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease
196. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death
197. +) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms
198. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
199. Programmed cell death in animal development
200. Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: Effects of NMDA antagonists, antioxidants and MAO inhibitors
201. Mitochondrial membrane permeabilization during the apoptotic process
202. Age-dependent effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)
203. Iron-melanin complex in substantia nigra of parkinsonian brains: An X-ray microanalysis
204. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease
205. Cell death mechanisms in Parkinson's disease
206. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease
207. Oxidative mechanisms in nigral cell death in Parkinson's disease
208. 6-Hydroxydopamine lesion of the rat substantia nigra: Time course and morphology of cell death
209. Activation of caspase-3 in developmental models of programmed cell death in neurons of the substantia nigra
210. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects
211. Contribution of p53-dependent caspase activation to neuronal cell death declines with neuronal maturation
212. Evidence for involvement of Bax and p53, but not caspases, in radiation- induced cell death of cultured postnatal hippocampal neurons
213. Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells
214. Effects of 6-hydroxydopamine on the uptake and storage of noradrenaline in sympathetic adrenergic neurons
215. Quantitation of fluorescence of biogenic monoamines
216. 3H-6-hydroxydopamine in adrenergic nerves
217. Transcription factor NF-ΚB is activated in primary amyloid b peptides and in neurones surrounding early plaques from patients with Alzheimer's disease
218. Role of apoptosis signal-regulating kinase in regulation of c-Jun N-terminal kinase pathway and apoptosis in sympathetic neurons
219. Activation of c-jun N-terminal kinase/stress-activated protein kinase and the decreased ratio of Bcl-2 to Bax are associated with the auto-oxidized dopamine-induced apoptosis in PC12 cells
220. JNK or IKK, AP-1 or NF-κB, which are the targets for MEK kinase 1 action?
221. Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: A mass fragmentographic study
222. Inhibition of caspase cascade by HTLV-I tax through induction of NF-kappaB nuclear translocation
223. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
224. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury
225. DNA fragmentation in human substantia nigra: Apoptosis or perimortem effect?
226. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c
227. Glutathione peroxidase activity in Parkinson's disease brain
228. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
229. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells
230. Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity
231. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
232. Medicamentous strategy for improving the quality of life in the senescence
233. 2+-mediated activation of c-Jun N-terminal kinase and nuclear factor κB by NMDA in cortical cell cultures
234. On the question of apoptosis in the parkinsonian substantia nigra
235. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
236. Free radical-generated neurotoxicity of 6-hydroxydopamine
237. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice
238. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in nonhuman primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level
239. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6- tetrahydropyridine intoxication in mouse
240. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study
241. The stress-activated protein kinase subfamily of c-Jun kinases
242. The inhibitors of apoptosis (IAPs) and their emerging role in cancer
243. + and paraquat on mitochondrial potential and oxidative stress
244. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
245. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
246. Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons
247. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ
248. +)-induced apoptosis independent of MAO-B inhibition
249. Clinical observations on the rate of progression of idiopathic parkinsonism
250. MEKK1 activates both IκB kinase α and IκB kinase β
251. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes
252. Antiapoptotic role of Nf-kappaB in the auto-oxidated dopamine-induced apoptosis of Pc12 cells
253. 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis
254. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death
255. Detection of dopamine-DNA adducts: Potential role in Parkinson's disease
256. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases
257. p53, the cellular gatekeeper for growth and division
258. Deciphering the pathways of life and death
259. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-κB
260. High constitutive NF-κB activity mediates resistance to oxidative stress in neuronal cells
261. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
262. Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease
263. Dopamine, 6-hydroxydopamine, iron, and dioxygen - Their mutual interactions and possible implication in the development of Parkinson's disease
264. Janus faces of NF-κB: Neurodestruction versus neuroprotection
265. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes
266. Status epilepticus induces p53 sequence-specific DNA binding in mature rat brain
267. 3H-6- hydroxydopamine in adrenergic nerves
268. The mitochondrion in cell death control: Certainties and incognita
269. Apoptosis inducing factor (AIF): A phylogenetically old, caspase-independent effector of cell death
270. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons
271. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease
272. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
273. Dopamine induces apoptosis through an oxidation-involved SPAK/JNK activation pathway
274. Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-kappaB in rats
275. Rate of cell death in parkinsonism indicates active neuropathological process
276. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
277. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor
278. Amine-mediated toxicity. The effects of dopamine, norepinephrine, 5- hydroxytryptamine, 6-hydroxydopamine, ascorbate, glutathione and peroxide on the in vitro activities of creatine and adenylate kinases in the brain of the rat
279. The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells
280. Motoneuron apoptosis is blocked by CEP-1347 (KT-7515), a novel inhibitor of the JNK signaling pathway
281. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults
282. Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: Studies on Parkinson's and incidental Lewy body disease
283. Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra
284. Apoptosis. Key to the mitochondrial gate
285. Parkinson's disease in a nationwide twin cohort
286. N-methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, (R)-salsolinol, in rat brains: In vivo microdialysis study
287. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders
288. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system
289. An endogenous dopaminergic neurotoxin: Implication for Parkinson's disease
290. Activation of NF-κB protects hippocampal neurons against oxidative-stress induced apoptosis: Evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration
291. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1
292. Intermediate filaments and ubiquitin: A new thread in the understanding of chronic neurodegenerative diseases
293. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: Implications for Parkinson's disease
294. Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage
295. Levodopa toxicity and apoptosis
296. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: Relevance to Parkinson's disease
297. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture
298. An exegesis of IAPs: Salvation and surprises from BIR motifs
299. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1
300. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
301. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
302. +) in isolated mitochondria from mouse brains
303. Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion
304. +) against mitochondria of mouse brain
305. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease
306. +) in ventral mesencephalic-striatal co-culture in rat
307. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys
308. Histochemical detection of apoptosis in Parkinson's disease
309. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients
310. bcl-2 protein is increased in the brain from parkinsonian patients
311. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain
312. Genetic toxicity of dopamine
313. Bcl-2 family members do not inhibit apoptosis by binding the caspase activator apaf-1
314. Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity
315. An induced proximity model for caspase-8 activation
316. N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins
317. A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol
318. N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease
319. New reaction pathways of dopamine under oxidative stress conditions: Nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6-hydroxydopamine and 6,7-dihydroxytetrahydroisoquinoline
320. Caspase structure, proteolytic substrates, and function during apoptotic cell death
321. Caspases: Killer proteases
322. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
323. Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice
324. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains
325. Caspases: The proteases of the apoptotic pathway
326. Linking extracellular survival signals and the apoptotic machinery
327. NF-κB: A crucial transcription factor for glial and neuronal cell function NF-ΚB: A crucial transcription factor for glial and neuronal cell function
328. Apoptosis and autoimmune disease
329. Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells
330. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: A histochemical and neurochemical study
331. Dopamine-induced programmed cell death in mouse thymocytes
332. Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson's disease
333. Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2
334. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity
335. +, but not 6-ODHA, induced cell death in a dopaminergic neuronal cell line
336. Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in the mouse
337. Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis
338. Genetic and functional changes in mitochondria associated with aging
339. Fragile mitochondrial DNA: The missing link in the apoptotic neuronal cell death in Parkinson's Disease
340. Nitrite- and peroxide-dependent oxidation pathways of dopamine: 6-nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide-induced neurotoxicity in neuronal degeneration
341. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex
342. Activation of nuclear transcription factor (NF-kappaB) is essential for dopamine-induced apoptosis in Pc12 cells
343. Lewy bodies of Parkinson's disease. Immune electron microscopic demonstration of neurofilament antigens in constituent filaments
344. Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic function of Bcl-2
345. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease
346. Induction of NF-κB-like transcription factors in brain areas susceptible to kainate toxicity
347. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in the rat brain
348. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain
349. Multiple redox regulation in NF-κB transcription factor activation
350. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium
351. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
352. Mutation in the α-synuclein gene identified in families with Parkinson's disease
353. Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice
354. The relationship between radioactivity and norepinephrine concentrations in the brains and hearts of mice following administration of labelled methyldopa or 6-hydroxydopamine (6-OHDA)
355. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
356. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity
357. Mechanisms of MPTP toxicity
358. Induction of p53 and its responsive gene products is associated with 6-hydroxydopamine-induced degeneration of dopaminergic neurons
359. Nuclear factor-kappaB contributes to excitotoxin-induced apoptosis in rat striatum
360. Cell suicide for beginners
361. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria
362. Bcl-2 family proteins
363. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment
364. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra
365. Apoptosis: The germs of death
366. Normal oxidative damage to mitochondrial and nuclear DNA is extensive
367. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
368. Carbon monoxide-induced Parkinsonism
369. Changes in lipid peroxidation induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine and 1-methyl-4-phenylpyridinium in mouse brain homogenates
370. Changes of metallothionein I + II proteins in the brain after 1-methyl-4-phenylpyridinium administration in mice
371. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro
372. The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis
373. Bcl-2 family members in the development and degenerative pathologies of the nervous system
374. p53 induction is associated with neuronal damage in the central nervous system
375. Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity
376. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain
377. Model experiments on the molecular mechanism of action of 6- hydroxydopamine
378. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo
379. 2-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo
380. Mitochondrial complex I deficiency in Parkinson's disease
381. Mitochondrial complex I deficiency in Parkinson's disease
382. Mitochondrial dysfunction in neurodegenerative disorders
383. BH4 domain of anti-apoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death
384. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1
385. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice
386. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors
387. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins
388. Nuclear factor-kappa B activation in permanent intraluminal focal cerebral ischemia in the rat
389. Neuroblastoma cells expressing the noradrenaline transporter are destroyed more selectively by 6-fluorodopamine than by 6-hydroxydopamine
390. Iron induces degeneration of nigrostriatal neurons
391. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra
392. Dose-dependent destruction of the coeruleus-cortical and nigral- striatal projections by MPTP
393. Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine
394. 2,4,5-tri-hydroxyphenetylamine, a new matbolite of 3,4-dihydroxyphenetylamine
395. Formation and rearrangements of aminochromes from a new metabolite of dopamine and some of its derivatives
396. Nonenzymatic conversions of dopamine to norepinephrine and trihydroxyphenethylamine
397. Mitochondrial DNA maintenance in vertebrates
398. + induced apoptotic cell death in SH-SY5Y neuroblastoma cells: An electron microscope study
399. The role of hydroxyl radical as a messenger in the activation of nuclear transcription factor NF-kappaB
400. The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein
401. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
402. Dopamine-induced apoptosis in human neuronal cells: Inhibition by nucleic acids antisense to the dopamine transporter
403. Hydroxyl radical attack on dopamine
404. Increase in extracellular dopamine in the striatum during cerebral ischemia: A study utilizing cerebral microdialysis
405. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
406. + inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1)
407. Boo, a novel negative regulator of cell death, interacts with Apaf-1
408. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: Potential implication in relation to the pathogenesis of Parkinson's disease
409. Alph-synuclein in Lewy bodies
410. Dopamine turnover and glutathione oxidation: Implications for Parkinson disease
411. TUNEL-positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
412. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization
413. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
414. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1- methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata
415. Mechanisms and genes of cellular suicide
416. Dopamine toxicity in neuroblastoma cells: Role of glutathione depletion by l-BSO and apoptosis
417. Comparison of the some pharmacological effects of certain 6-substituted dopamine derivatives with the reserpine guanethidine and metaraminol
418. 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: Independent of mitochondrial energy metabolism
419. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism
420. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2
421. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy
422. Mitogen-activated protein kinase cascades and regulation of gene expression
423. Molecular characterization of mitochondrial apoptosis-inducing factor
424. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease
425. Origin and functional consequences of the complex I defect in Parkinson's disease
426. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family
427. Inhibition of nuclear factor kappa B (NF-κB) activity induces nerve growth factor-resistant apoptosis in PC12 cells
428. VMAT2 knockout mice: Heterozygotes display reduced amphetamine- conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity
429. Involvement of caspase-like proteinases in apoptosis of neuronal PC12 cells and primary cultured microglia induced by 6-hydroxydopamine
430. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons
431. Parkinson disease in twins: An etiologic study
432. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining
433. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease
434. Increased Caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease
435. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: Evidence from proton microprobe elemental microanalysis
436. +)
437. Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)
438. Diminished effect of sympathetic nerve stimulation in cats pretreated with 5-hydroxyDOPA; formation and liberation of false adrenergic transmitters
439. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine
440. Apoptosis in the pathogenesis and treatment of disease
441. Caspases: Enemies within
442. Differential effects of staurosporine and retinoic acid on the vulnerability of the SH-SY5Y neuroblastoma cells: Involvement of bcl-2 and p53 proteins
443. Participation of active oxygen species in 6-hydroxydopamine toxicity to a human neuroblastoma cell line
444. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
445. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons
446. Bcl-2 and Bax proteins in Lewy bodies from patients with Parkinson's disease and Diffuse Lewy body disease
447. Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase
448. Electron microscopic localization of 5-hydroxydopamine, a new false symapthetic neurotransmitter
449. An electron microscopic study of selective acute degeneration of sympathetic nerve terminals after administration of 6-hydroxydopamine
450. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity
451. 6-Hydroxydopamine induces thymocyte apoptosis in mice
452. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation
453. + neurotoxicity by N-methyl-d- aspartate antagonists
454. Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease
455. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons
456. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts
457. Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain
458. Pathological findings in idiopathic orthostatic hypotension. Its relationship with Parkinson's disease
459. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease
460. The α-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases. European consortium on genetic susceptibility in Parkinson's Disease
461. Cell death in development
462. Dopamine and iron induce apoptosis in PC12 cells
463. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of parkinson's disease
464. Comparison between the timing of JNK activation, c-Jun phosphorylation, and onset of death commitment in sympathetic neurones
465. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice expressing the baculoviral caspase inhibitor p35
466. Rescue from death but not from functional impairment: Capsase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals
467. Localization of damage induced by reactive oxygen species in cultured cells
468. Expression of Bcl-2 in adult human brain regions with special reference to neurodegenerative disorders
469. Effect of 6-hydroxydopamine on oxidative phosphorylation and on monoamine oxidase activity
470. Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: A (p20/p10)2 homodimer
471. Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis
472. Induction of apoptosis in catecholaminergic PC12 cells by l-dopa. Implications for the treatment of Parkinson's disease
473. NF-kappaB anti-apoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c- IAP2 to suppress caspase-8 activation
474. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
475. 2+-induced apoptosis through calcineurin dephosphorylation of BAD
476. Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons
477. Life, death, and the pursuit of apoptosis
478. Dopamine: A novel antitumor agent active against B-16 melanoma in vivo
479. Structure and mechanism of interleukin-1 beta converting enzyme
480. Cleavage of Bax enhances its cell death function
481. The toxicity of 6-hydroxydopamine on PC12 and P19 cells
482. Maternal inheritance in Parkinson's disease
483. Relationships between the mitochondrial transmembrane potential, ATP concentration, and cytotoxicity in isolated rat hepatocytes
484. +, apoptosis induced by 6-OHDA in PC12 cells is independent of mitochondrial inhibition
485. + toxicity in nigral dopaminergic neurones
486. Cell death and apoptosis regulating proteins in Parkinson's disease - A cautionary note
487. Opposing effects of ERK and JNK-p38 MAP Kinases on apoptosis
488. Bax involvement in p53-mediated neuronal cell death
489. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases
490. Possible involvement of catalase in the protective effect of interleukin-6 against 6-hydroxydopamine toxicity in PC12 cells
491. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo
492. Essential role of CED-4 oligomerization in CED-3 activation and apoptosis
493. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2
494. +), and inhibition by epidermal growth factor in GH3 cells
495. Transducing signals of life and death
496. The Caenorhabditis elegans cell death gene ced-4 encodes a novel protein and is expressed during the period of extensive programmed cell death
497. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme
498. Mitochondrial control of nuclear apoptosis
499. Superoxide radical production during the autoxidation of 1-methyl-4- phenyl-2,3-dihydropyridinium perchlorate
500. Secondary excitotoxicity contributes to dopamine-induced apoptosis of dopaminergic neuronal cultures
501. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase
502. Apaf-1, a human protein homologous to C. elegans Ced-4, participates in cytochrome c-dependent activation of caspase-3
503. Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells
504. Monoamine-induced apoptotic neuronal cell death
505. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - A possible novel pathogenetic mechanism in Parkinson's disease
506. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis
507. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity
508. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion